Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | HOOK |
---|---|---|
09:32 ET | 10367 | 0.7574 |
09:34 ET | 20042 | 0.74 |
09:36 ET | 2500 | 0.75 |
09:38 ET | 13240 | 0.76 |
09:39 ET | 2171 | 0.7774 |
09:48 ET | 5500 | 0.7774 |
09:50 ET | 9425 | 0.7645 |
09:54 ET | 134 | 0.752 |
09:56 ET | 2755 | 0.7596 |
09:57 ET | 100 | 0.7645 |
09:59 ET | 1850 | 0.778 |
10:01 ET | 200 | 0.789 |
10:06 ET | 253 | 0.7897 |
10:12 ET | 5000 | 0.7895 |
10:14 ET | 5300 | 0.78 |
10:15 ET | 2000 | 0.784 |
10:21 ET | 1074 | 0.78 |
10:24 ET | 1500 | 0.7762 |
10:28 ET | 3100 | 0.77515 |
10:30 ET | 3300 | 0.7685 |
10:35 ET | 100 | 0.77515 |
10:37 ET | 3600 | 0.7799 |
10:44 ET | 800 | 0.761 |
10:46 ET | 29600 | 0.7899 |
10:50 ET | 685 | 0.772301 |
10:51 ET | 10000 | 0.7723 |
10:53 ET | 500 | 0.7858 |
11:00 ET | 100 | 0.7771 |
11:09 ET | 1200 | 0.7723 |
11:13 ET | 200 | 0.7723 |
11:15 ET | 100 | 0.7723 |
11:18 ET | 25380 | 0.785 |
11:24 ET | 100 | 0.7819 |
11:27 ET | 1000 | 0.782 |
11:29 ET | 100 | 0.7791 |
11:40 ET | 1600 | 0.77905 |
11:42 ET | 100 | 0.7829 |
11:44 ET | 1300 | 0.7753 |
11:49 ET | 800 | 0.7781 |
11:51 ET | 5613 | 0.7829 |
11:54 ET | 120 | 0.7607 |
12:03 ET | 20100 | 0.7718 |
12:09 ET | 100 | 0.7765 |
12:16 ET | 100 | 0.77 |
12:20 ET | 377 | 0.776451 |
12:21 ET | 100 | 0.7765 |
12:27 ET | 200 | 0.77 |
12:32 ET | 1178 | 0.7829 |
12:34 ET | 800 | 0.77 |
12:43 ET | 100 | 0.7712 |
12:50 ET | 400 | 0.77 |
12:52 ET | 2400 | 0.7829 |
12:56 ET | 600 | 0.7765 |
12:59 ET | 500 | 0.77 |
01:08 ET | 200 | 0.77 |
01:12 ET | 687 | 0.775 |
01:14 ET | 100 | 0.7725 |
01:15 ET | 300 | 0.775 |
01:17 ET | 1000 | 0.775 |
01:32 ET | 19272 | 0.7819 |
01:33 ET | 7715 | 0.7742 |
01:35 ET | 850 | 0.774739 |
01:37 ET | 582 | 0.7742 |
01:39 ET | 500 | 0.7829 |
01:42 ET | 100 | 0.7829 |
01:48 ET | 200 | 0.7742 |
01:50 ET | 1099 | 0.7742 |
01:51 ET | 100 | 0.7799 |
01:53 ET | 500 | 0.7743 |
01:55 ET | 100 | 0.7798 |
02:04 ET | 200 | 0.77 |
02:06 ET | 722 | 0.77 |
02:11 ET | 100 | 0.7744 |
02:13 ET | 16385 | 0.77 |
02:15 ET | 33854 | 0.773783 |
02:18 ET | 1037 | 0.76 |
02:20 ET | 1444 | 0.768 |
02:22 ET | 300 | 0.76 |
02:24 ET | 400 | 0.7601 |
02:27 ET | 200 | 0.7601 |
02:29 ET | 1401 | 0.764 |
02:31 ET | 9887 | 0.7601 |
02:33 ET | 1596 | 0.776 |
02:36 ET | 600 | 0.776 |
02:38 ET | 2746 | 0.7699 |
02:40 ET | 200 | 0.77 |
02:42 ET | 1851 | 0.7699 |
02:44 ET | 1280 | 0.762 |
02:45 ET | 100 | 0.77 |
02:47 ET | 100 | 0.77 |
02:49 ET | 7981 | 0.761 |
02:51 ET | 599 | 0.7699 |
02:54 ET | 1000 | 0.7603 |
02:56 ET | 1150 | 0.761 |
03:00 ET | 100 | 0.761 |
03:03 ET | 100 | 0.761 |
03:05 ET | 602 | 0.7697 |
03:07 ET | 100 | 0.761 |
03:14 ET | 200 | 0.761 |
03:16 ET | 100 | 0.761 |
03:18 ET | 200 | 0.765 |
03:20 ET | 4258 | 0.761 |
03:21 ET | 100 | 0.7603 |
03:23 ET | 200 | 0.7604 |
03:32 ET | 100 | 0.765 |
03:39 ET | 784 | 0.769 |
03:41 ET | 200 | 0.769 |
03:48 ET | 200 | 0.7684 |
03:50 ET | 1132 | 0.7604 |
03:52 ET | 999 | 0.7626 |
03:54 ET | 100 | 0.762 |
03:56 ET | 221 | 0.766 |
03:57 ET | 2100 | 0.76305 |
03:59 ET | 1587 | 0.7663 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
HOOKIPA Pharma Inc | 76.0M | 0.0x | --- |
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $76.0M |
---|---|
Revenue (TTM) | $20.1M |
Shares Outstanding | 99.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-1.07 |
Book Value | $0.91 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 3.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -485.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.